spacer
home > ebr > autumn 2018 > produce potential
PUBLICATIONS
European Biopharmaceutical Review

Produce Potential

Custom-made oligonucleotides are commonly produced by solid phase synthesis, where the sequence is grown chemically on a resin in a 3’-5’ direction (1). Each amidite/nucleotide monomer has a 5’ trityl-blocking group to prevent addition of more than one nucleotide in each synthesis step that is cleaved off prior to the start of next coupling reaction (2). The completed oligonucleotide is released from the solid support by ammonolysis. Although the solid-phase technology gives a very low synthesis error rate, a small percentage of sequences where the oligonucleotide has deletions are always present, such as N-1 sequences and depurinations (where the nucleic base has been cleaved off), or extra insertions of elements (eg, N+1) (3). The frequency of failures increases with length of the synthesised oligonucleotide.

Antisense oligonucleotides (ASOs) are DNA sequences designed to bind complementary RNA targets (mainly mRNAs) to affect gene expression. Antisense gene therapy is emerging as one of the most promising therapeutics for various diseases, such as cancer (4-5). As of 2017, six FDAapproved ASO-based therapies are on the market, and many are in clinical trials (6). Most of the ASO molecules currently in clinical trials are phosphorothioates: modified nucleic acids in which one of the non-bridging oxygens on the phosphate backbone is replaced by a sulphur (7). This modification increases the half-life of the oligonucleotide. In addition to the mentioned synthesis errors, the phosphorothioate linkage of phophorotioates might be oxidised to a phosphodiester linkage, (P=O)x.

Due to the stringent requirements in therapeutic applications, efficient purification schemes to produce oligonucleotides with a minimum of erroneous sequences are a necessity.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Cecilia Unoson is a Senior Application Scientist at Bio-Works Technologies and has a PhD from the Department of Cellular and Molecular Biology at Uppsala University, Sweden. Cecilia has 15 years’ experience working with oligonucleotides, especially within the RNA field, where she has focussed on regulatory RNAs and the CRISPR-Cas9 system. She also has a strong background in proteomics and has worked in both small and large biotech companies. Today, Cecilia is responsible for the oligonucleotide applications at Bio-Works Technologies.

Dr Lars Haneskog is the R&D director at Bio-Works Technologies, with a PhD in bioseparation and membrane proteins from Uppsala University, Sweden. The research focus was bioseparation and membrane proteins. He has more than 20 years of experience in chromatographic purification of biomolecules, and development of chromatography products.
spacer
Dr Cecilia Unoson
spacer
spacer
spacer
Dr Lars Haneskog
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Applikon Biotechnology collaborates with Emerson for new Life Sciences R&D solution: V-Control

Applikon Biotechnology has launched V-Control for R&D scale bioreactors, a sophisticated automation solution developed in collaboration with Emerson. It uses a scaled version of Emerson’s DeltaV distributed control system (DCS), DeltaV Discovery, designed for research and discovery laboratories. V-Control enables easy process control and data up-scaling in one platform. Furthermore, it provides organizations that already use the DeltaV DCS at production scale with reliable automation scaled to fit the needs of the laboratory environment, making tech transfer easier.
More info >>

White Papers

Modular Feeding Systems for Prefilled Syringes and Injection Devices

Dividella

The pre-filled syringe and injection device is an increasingly attractive presentation for both new and established parenteral pharmaceuticals. We will explore how innovative carton packaging solutions can enhance this presentation whilst meeting the stringent requirements of product protection.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement